查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1421548

全球输液和口服铁剂市场 - 热门市场（2024-2029）

Global IV & Oral Iron Drugs Market - Focused Insights 2024-2029
出版日期: | 出版商: Arizton Advisory & Intelligence | 英文 126 Pages | 订单完成后即时交付

价格

2023年全球输液和口服铁剂市场规模达76.6亿美元。预计该市场将经历强劲成长，到 2029 年复合年增长率将达到 13.47%。这种快速成长的主要驱动力是全球范围内缺铁 (ID) 和缺铁性贫血 (IDA) 盛行率的不断上升以及患者对有效治疗方案的认识不断提高。导致铁缺乏的慢性疾病，如慢性肾臟病（CKD）、心臟衰竭、胃肠道疾病和癌症，尤其是手术患者的发生率不断增加，也推动了市场的扩张。

推动市场成长的主要因素包括对无右旋糖酐铁治疗药物的需求不断增加以及透析和非透析肾病患者对铁补充剂的需求不断增加。该市场还受益于最新一代静脉和口服铁製剂的开发，这些製剂目前正在进行临床试验，旨在扩大适应症并改善治疗结果。

Vifor Pharma 等市场领导者透过 Ferinject（在美国以 Injectafer 名称出售）和 Venofer 等产品做出了重大贡献，这些产品在透析患者中特别受欢迎。口服铁剂市场由处方药和非处方药产品组成，儘管增速慢于静脉铁剂，但正在稳步扩张，由于其高成本效益，预计在新兴和低收入国家将出现强劲增长。

市场成长不仅在已开发国家，在亚洲、非洲和拉丁美洲的新兴国家也很显着，这些国家缺铁是严重的健康挑战。医院药房营运创新和零售商的参与进一步推动了这种成长，提高了消费者的可及性和意识。

医院药房部门预计将发展壮大，因为它为铁製剂提供专业服务。同时，零售商由于其即时的产品可用性和专家指导而继续发挥重要作用。CKD 患者缺铁的盛行率估计约为 70%，这凸显了透过静脉注射和口服铁补充剂进行铁治疗的迫切需求。

该报告研究了全球输液和口服铁剂市场，提供了市场概述、给药途径趋势、患者群体、分销管道、应用、地区以及参与市场的公司概况。

目录

第一章 输液和口服铁剂市场概况

第二章 输液与口服铁剂市场

第三章输液和口服铁剂市场收入预测（2023-2029年；十亿美元）

  • 世界:按管理途径划分的预计收入（2023-2029 年；十亿美元）
  • 世界:按患者群体划分的预期收入（2023-2029 年；十亿美元）
  • 全球:按分销管道划分的预期收入（2023-2029 年；十亿美元）
  • 世界:按应用划分的预计收入（2023-2029 年；十亿美元）

第四章 主要地区概况

  • 北美
  • 美国
  • 加拿大
  • 欧洲
  • 德国
  • 英国
  • 法国
  • 义大利
  • 西班牙
  • 亚太地区
  • 日本
  • 中国
  • 澳大利亚
  • 拉丁美洲
  • 巴西
  • 墨西哥
  • 阿根廷
  • 中东/非洲
  • 土耳其
  • 南非
  • 沙乌地阿拉伯

第五章输液与口服铁剂市场前景与机会

  • IV 和口服铁剂市场机会和趋势
  • 静脉注射和口服铁剂市场的驱动因素
  • 静脉注射和口服铁剂市场的限制因素

第六章 输液及口服铁剂产业概况

  • IV 和口服铁剂市场 - 竞争格局
  • 静脉注射和口服铁剂市场 – 主要供应商概况
  • 静脉注射和口服铁剂市场—其他知名供应商
  • IV 和口服铁剂市场 – 关键策略建议

第7章附录

Product Code: AFI24006

The global IV and Oral Iron Drugs market, valued at $7.66 billion in 2023, will experience robust growth by 2029, expanding at a CAGR of 13.47%. This surge is primarily driven by the increasing prevalence of Iron Deficiency (ID) and Iron Deficiency Anemia (IDA) globally, coupled with a heightened awareness among patients about effective treatment options. The market's expansion is further propelled by the rising occurrence of chronic diseases such as Chronic Kidney Disease (CKD), heart failure, gastrointestinal disorders, and cancer, which can lead to iron deficiency, particularly in surgical patients.

Key factors fueling market growth include the growing demand for dextran-free iron therapeutics and the rising need for iron drugs among dialysis and non-dialysis kidney patients. The market also benefits from the development of investigational latest generation IV & oral iron drugs with broader indications and improved treatment outcomes.

Market leaders like Vifor Pharma are significantly contributing with products such as Ferinject (marketed as Injectafer in the US) and Venofer, which are gaining traction, especially among dialysis patients. The oral iron drug segment, comprising both prescription and OTC preparations, is expanding steadily, although slower than IV iron drugs, with significant growth in emerging and low-income countries due to their cost-effectiveness.

The market's growth is not just confined to developed nations; it's also significant in developing countries across Asia, Africa, and Latin America, where iron deficiency poses a severe health challenge. This growth is further augmented by innovations in hospital pharmacy practice and retail store involvement, facilitating accessibility and awareness among consumers.

The hospital pharmacies segment is expected to grow due to their specialized services in iron medicines. At the same time, retail stores continue to play a crucial role due to immediate product availability and expert guidance. The prevalence of iron deficiency in CKD patients, which is estimated to be around 70%, highlights the critical need for iron therapy with IV and oral iron drugs.

As the global IV & oral iron drugs market evolves, key vendors like Vifor Pharma, Daiichi Sankyo Group, AMAG Pharmaceuticals, and others focus on product innovations and expanded label approvals to meet the growing demands and adapt to new patient groups. The market, characterized by the presence of global, regional, and local players, is highly competitive with a wide array of branded and generic drug offerings.

KEY HIGHLIGHTS:

  • The IV & oral iron drugs market represents a rapidly growing and most effective category of therapeutics that helps individuals with ID & IDA to improve their quality of life.
  • By route of administration, the intravenous (IV) segment was valued at $4.40 billion in 2023. This growth mainly results from the expected launch of branded IV iron drugs in new markets and expanded indication approval for existing commercially available brands. One of the primary reasons for this significant growth rate is the increased uptake of branded IV drugs in the US and European markets.
  • By patient group, the adult segment is going to witness notable growth during the forecast period. In 2023, the adult segment accounted for 83.33% of the global IV & oral iron drugs market. The segment is dominating the market due to the higher incidence/ prevalence of ID and IDA among elderly people across the world.
  • By distribution channel, the hospital pharmacies segment is expected to grow at a significant CAGR. Hospital pharmacies offer iron drugs with adequate discounts and rebates. Thus offering a cost-effective way to minimize the burden on patients and healthcare systems.
  • By application, In 2023, the nephrology segment accounted for 60.84% of the global IV & oral iron drugs market. The market for iron drugs in nephrology is increasing faster, and the trend is likely to continue during the forecast period due to the rising prevalence of CKD worldwide. The segment accounted for the largest market share owing to the increasing uptake of iron drugs to treat CKD.
  • CSL Vifor, Covis Pharmaceuticals, Daiichi Sankyo, Akebia Therapeutics, Shield Therapeutics, and others are some of the leading players currently dominating the global IV & Oral iron drugs market. The major players focus on strategic acquisitions and collaborations with emerging players to enter the IV & Oral Iron Drugs market and to gain access to commercially launched products.

REPORT HIGHLIGHTS

PRODUCT SEGMENTATION & FORECAST

  • Route of Administration
  • Intravenous
  • Oral
  • Patient Group
  • Adults
  • Pediatrics
  • Distribution Channel
  • Hospital Pharmacies
  • Offline Retail Pharmacies
  • Online Channels
  • Application
  • Nephrology
  • Obstetrics & Gynaecology
  • Surgery
  • Gastroenterology
  • Oncology
  • Heart Failure
  • MARKET STRUCTURE
  • Market Dynamics
  • Competitive Landscape of IV & Oral Iron Drugs Market
  • Key Vendors
  • Other Prominent Vendors
  • APPENDIX
  • Research Methodology
  • Abbreviations
  • About Arizton

VENDORS LIST

  • CSL Vifor
  • Daiichi Sankyo
  • Covis Pharmaceuticals
  • Akebia Therapeutics
  • Shield Therapeutics
  • Pharmacosmos
  • AbbVie
  • Sanofi
  • AOP Orphan Pharmaceuticals
  • Azad Pharmaceuticals
  • Pfizer
  • Ciron Drugs & Pharmaceuticals
  • Rockwell Medical
  • Salveo Lifecare
  • Sunny Pharmaceuticals
  • Zydus LifeSciences
  • Nippon Shinyaku
  • Alinter Group
  • Alora Pharmaceuticals
  • DSE Healthcare
  • GSK plc

TABLE OF CONTENTS

CHAPTER - 1: IV & Oral Iron Drugs Market Overview

  • Executive Summary
  • Key Findings

CHAPTER - 2: IV & Oral Iron Drugs Market

  • GLOBAL: Projected Revenue of IV & Oral Iron Drugs Market (2023-2029; $Billions)

CHAPTER - 3: IV & Oral Iron Drugs Market Segmentation Data

  • GLOBAL: Projected Revenue by Route of Administration (2023-2029; $Billions)
  • Intravenous
  • Oral
  • GLOBAL: Projected Revenue by Patient Group (2023-2029; $Billions)
  • Adults
  • Pediatrics
  • GLOBAL: Projected Revenue by Distribution Channel (2023-2029; $Billions)
  • Hospital Pharmacies
  • Offline Retail Pharmacies
  • Online Channels
  • GLOBAL: Projected Revenue by Application (2023-2029; $Billions)
  • Nephrology
  • Obstetrics & Gynecology
  • Surgery
  • Gastroenterology
  • Oncology
  • Heart Failure

CHAPTER - 4: Key Regions Overview

  • North America: Projected Revenue of IV & Oral Iron Drugs Market (2023-2029; $Billions)
  • Projected Revenue of IV & Oral Iron Drugs Market in US
  • Projected Revenue of IV & Oral Iron Drugs Market in Canada
  • Europe: Projected Revenue of IV & Oral Iron Drugs Market (2023-2029; $Billions)
  • Projected Revenue of IV & Oral Iron Drugs Market in Germany
  • Projected Revenue of IV & Oral Iron Drugs Market in UK
  • Projected Revenue of IV & Oral Iron Drugs Market in France
  • Projected Revenue of IV & Oral Iron Drugs Market in Italy
  • Projected Revenue of IV & Oral Iron Drugs Market in Spain
  • APAC: Projected Revenue of IV & Oral Iron Drugs Market (2023-2029; $Billions)
  • Projected Revenue of IV & Oral Iron Drugs Market in Japan
  • Projected Revenue of IV & Oral Iron Drugs Market in China
  • Projected Revenue of IV & Oral Iron Drugs Market in Australia
  • Latin America: Projected Revenue of IV & Oral Iron Drugs Market (2023-2029; $Billions)
  • Projected Revenue of IV & Oral Iron Drugs Market in Brazil
  • Projected Revenue of IV & Oral Iron Drugs Market in Mexico
  • Projected Revenue of IV & Oral Iron Drugs Market in Argentina
  • Middle East & Africa: Projected Revenue of IV & Oral Iron Drugs Market (2023-2029; $Billions)
  • Projected Revenue of IV & Oral Iron Drugs Market in Turkey
  • Projected Revenue of IV & Oral Iron Drugs Market in South Africa
  • Projected Revenue of IV & Oral Iron Drugs Market in Saudi Arabia

CHAPTER - 5: IV & Oral Iron Drugs Market Prospects & Opportunities

  • IV & Oral Iron Drugs Market Opportunities & Trends
  • IV & Oral Iron Drugs Market Drivers
  • IV & Oral Iron Drugs Market Constraints

CHAPTER - 6: IV & Oral Iron Drugs Industry Overview

  • IV & Oral Iron Drugs Market - Competitive Landscape
  • IV & Oral Iron Drugs Market - Key Vendor Profiles
  • IV & Oral Iron Drugs Market - Other Prominent Vendors
  • IV & Oral Iron Drugs Market - Key Strategic Recommendations

CHAPTER - 7: Appendix

  • Research Methodology
  • Abbreviations
  • About Arizton

List Of Exhibits

LIST OF EXHIBITS

Exhibit 1: Projected Revenues of IV & Oral Iron Drugs in Global ($ Bn)

Exhibit 2: Market Size & Forecast - Intravenous ($ Bn)

Exhibit 3: Market Size & Forecast - Oral ($ Bn)

Exhibit 4: Market Size & Forecast - Adults ($ Bn)

Exhibit 5: Market Size & Forecast - Pediatrics ($ Bn)

Exhibit 6: Market Size & Forecast - Hospital Pharmacies ($ Bn)

Exhibit 7: Market Size & Forecast - Offline Retail Stores

Exhibit 8: Market Size & Forecast - Online Channels ($ Bn)

Exhibit 9: Market Size & Forecast - Nephrology ($ Bn)

Exhibit 10: Market Size & Forecast - Obstetrics & Gynecology ($ Bn)

Exhibit 11: Market Size & Forecast - Surgery ($ Bn)

Exhibit 12: Market Size & Forecast - Gastroenterology ($ Bn)

Exhibit 13: Market Size & Forecast - Oncology ($ Bn)

Exhibit 14: Market Size & Forecast - Heart Failure ($ Bn)

Exhibit 17: Projected Revenues of IV & Oral Iron Drugs in North America ($ Bn)

Exhibit 18: Projected Revenues of IV & Oral Iron Drugs in US ($ Bn)

Exhibit 19: Projected Revenues of IV & Oral Iron Drugs in Canada ($ Bn)

Exhibit 20: Projected Revenues of IV & Oral Iron Drugs in Europe ($ Bn)

Exhibit 21: Projected Revenues of IV & Oral Iron Drugs in Germany ($ Bn)

Exhibit 22: Projected Revenues of IV & Oral Iron Drugs in UK ($ Bn)

Exhibit 23: Projected Revenues of IV & Oral Iron Drugs in France ($ Bn)

Exhibit 24: Projected Revenues of IV & Oral Iron Drugs in Italy ($ Bn)

Exhibit 25: Projected Revenues of IV & Oral Iron Drugs in Spain ($ Bn)

Exhibit 26: Projected Revenues of IV & Oral Iron Drugs in APAC ($ Bn)

Exhibit 27: Projected Revenues of IV & Oral Iron Drugs in Japan ($ Bn)

Exhibit 28: Projected Revenues of IV & Oral Iron Drugs in China ($ Bn)

Exhibit 29: Projected Revenues of IV & Oral Iron Drugs in Australia ($ Bn)

Exhibit 30: Projected Revenues of IV & Oral Iron Drugs in Latin America ($ Bn)

Exhibit 31: Projected Revenues of IV & Oral Iron Drugs in Brazil ($ Bn)

Exhibit 32: Projected Revenues of IV & Oral Iron Drugs in Mexico ($ Bn)

Exhibit 33: Projected Revenues of IV & Oral Iron Drugs in Argentina ($ Bn)

Exhibit 34: Projected Revenues of IV & Oral Iron Drugs in Middle East & Africa ($ Bn)

Exhibit 35: Projected Revenues of IV & Oral Iron Drugs in Turkey ($ Bn)

Exhibit 36: Projected Revenues of IV & Oral Iron Drugs in South Africa ($ Bn)

Exhibit 37: Projected Revenues of IV & Oral Iron Drugs in Saudi Arabia ($ Bn)

List Of Tables

LIST OF TABLES

Table 1: Key Market Trends in IV & Oral Iron Drugs Market

Table 2: Key Market Enablers in IV & Oral Iron Drugs Market

Table 3: Key Market Constraints in IV & Oral Iron Drugs Market

Table 4: Strategic Recommendations in IV & Oral Iron Drugs Market